Paper Review Records
全部论文审稿周期
24 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接
153
天
In Utero Exposure to Acetazolamide and Pregnancy Outcomes: A Cohort Study
作者
Camille Reinaud; Maria Hoeltzenbein; Valérie Touitou; Catherine Vauzelle; Elisabeth Elefant; Delphine Beghin; Benoît Marin; Bénédicte Coulm展开收起
作者单位
1. AP-HP Sorbonne Université, Hôpital Pitié-Salpêtrière, Département de Santé Publique, Centre de Référence sur les Agents Tératogènes (CRAT), 75013 Paris, France; 2. Embryotox Center of Clinical Teratology and Drug Safety in Pregnancy, Institute of Clinical Pharmacology and Toxicology, Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin, Germany; 3. Limbach Genetics MVZ Humangenetik Bremen, Bremen, Germany; 4. Sorbonne Université, Hôpital Pitié-Salpêtrière, Département d’Ophtalmologie, 75013 Paris, France; 5. Sorbonne Université, INSERM, Institut Pierre-Louis d’Épidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Département de Santé Publique, Centre de Référence sur les Agents Tératogènes (CRAT), 75013 Paris, France; 6. Département Universitaire de Maïeutique, Sorbonne Université, Paris, France展开收起
201
天
Medication-Related Osteonecrosis of the Jaw: An Unmasking Disproportionality Analysis of VigiBase, the WHO Spontaneous Reporting Database
作者
Elena Arzenton; Antonia Marcianò; Federico Gozzi; Domenico Levita; Francesco Maccarrone; Ugo Moretti; Fabio Scapini; Gianluca Trifirò; Giacomo Oteri; Marco Tuccori展开收起
作者单位
1. Department of Diagnostics and Public Health, Section of Pharmacology, University of Verona, Verona, Italy; 2. Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy展开收起
97
天
Discontinuation of Additional Risk Minimisation Measure Tools Implemented at Authorisation for Centrally Authorised Medicinal Products in the EU
作者
Sharon C. M. Essink; Inge M. Zomerdijk; Valerie Strassmann; Thomas Goedecke; Sabine M. J. M. Straus; Helga Gardarsdottir; Marie L. De Bruin展开收起
作者单位
1. Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands; 2. Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, The Netherlands; 3. European Medicines Agency, Amsterdam, The Netherlands; 4. Department of Clinical Pharmacy, University Medical Centre Utrecht, Utrecht, The Netherlands; 5. Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavik, Iceland展开收起
188
天
Understanding the Relationship between Causality Assessment and Drug Labeling Practices: An Evaluation of US Regulations and FDA Policy Documents
作者
Sarah Tanveer; Wendy Camelo Castillo; Linda Wastila; Tarek A. Hammad; Catherine E. Cooke; John P. A. Ioannidis; Peter Doshi展开收起
作者单位
1. Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, USA; 2. Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, USA; 3. Medical Safety for Marketed Products Development, Plasma-Derived Therapies, Medical Devices, and Vaccines, Takeda Development Center Americas, Inc., Cambridge, USA; 4. Departments of Medicine and of Epidemiology and Population Health, Stanford University, Stanford, USA展开收起
86
天
Toward a Framework for Case Identification in Pharmacovigilance: Not All Reports are Created Equal
作者
Michele Fusaroli; Joana Félix China; D. Sartori; Valentina Giunchi; Linda Härmark; Joep Scholl; Florence van Hunsel; G. Niklas Norén; Johan Ellenius展开收起
作者单位
1. Uppsala Monitoring Centre, Uppsala, Sweden; 2. Drug Safety Research Unit, Southampton, UK; 3. Netherlands Pharmacovigilance Centre Lareb, MH’s-Hertogenbosch, The Netherlands; 4. Department of PharmacoTherapy, Epidemiology, and Economics, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Groningen, The Netherlands展开收起
171
天
EudraScore: Modification of the Vigi4Eudra-score for the Assessment of the Completeness of Adverse Drug Reaction Reports in EudraVigilance
作者
Diana Dubrall; Patrick Christ; Dennis Lex; Robert Hoffmann; Thomas Grüger; Matthias Schmid; Bernhardt Sachs展开收起
作者单位
1. University of Bonn, University Hospital Bonn, Institute for Medical Biometry, Informatics and Epidemiology, Bonn, Germany; 2. Research Division, Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany; 3. Pharmacovigilance Division, Federal Institute for Drugs and Medical Devices, Bonn, Germany; 4. Department for Dermatology and Allergy, University Hospital RWTH Aachen, Aachen, Germany展开收起
FAQ
DRUG SAFETY审稿要多久?
截至2026-11-18,CrushSCI 收录了 DRUG SAFETY 的 24 篇完整审稿记录。最快一篇从收稿到录用用了 4 天(ISoP MENA Chapter: Strategic Development and Future Directions Following a Decade of Strengthening Pharmacovigilance in the Middle East and North Africa,2026-08-16 收稿,2026-08-20 录用),最慢一篇用了 288 天;平均 126.8 天,中位数 119 天。最快这篇的日期间隔异常短,建议点开原文核对。
Expert Matching · Case Demo
把投稿要求,转成可验证的期刊方案
说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。
